Simpler, More Transparent Analysis Will Make Circular A-4 More Valuable to the Regulatory Process
Public interest comment filed jointly by GW's Christopher Carrigan and Stuart Shapiro of Rutgers University
Public Comments & Testimonies
Scholarly analysis of the potential effects of particular rulemakings from federal agencies, and advice to Congress on how to improve the rulemaking process by GW Regulatory Studies Center scholars.
"Your input and expertise during the drafting of the Early Participation in Regulations Act of 2019 and SMART Act of 2019 was invaluable."
Senator Kyrsten Sinema (D-AZ)
Senator James Lankford (R-OK)
Joint statement
Public interest comment on the OMB Draft Circular A-4 by Susan Dudley, former Administrator of the Office of Information and Regulatory Affairs
On Draft Circular A4, Behavioral Biases, and Discount Rates
Public Interest Comment on the Office of Management and Budget's Draft Circular A4 concerning benefit-cost analysis
Distributional Weights Should Be Dropped from the Draft Circular A-4
Weighting costs and benefits could result in large losses in efficiency
Public Interest Comment on HUD's Affirmatively Furthering Fair Housing proposal
Recommendations for improving the framework around fair housing planning, assessment and engagement
Public Interest Comment on the DEA Proposed Rules on Telemedicine and Buprenorphine
Improving access to opioid use disorder treatments by making permanent pandemic-era flexibilities
Broadening Public Engagement in the Federal Regulatory Process
Public interest comment with input on public engagement initiatives by the Office of Information and Regulatory Affairs
SAMHSA Proposed Rule on Medications for the Treatment of Opioid Use Disorder
Public interest comment submitted in response to SAMHSA proposal to extend COVID-19 pandemic era flexibilities for accessing treatments for opioid use disorder
Factors Contributing to the Infant Formula Shortage
The Federal Trade Commission (FTC) has solicited public comments on the factors that may have contributed to the recent infant formula shortage.
FDA & Wholesale Drug Distributors
Dylan Desjardins offers ways for the FDA to improve the underlying assumptions, examination of alternatives, and review of unintended consequences for this proposed rule.